Search

Your search keyword '"Ringelstein-Harlev, Shimrit"' showing total 17 results

Search Constraints

Start Over You searched for: Author "Ringelstein-Harlev, Shimrit" Remove constraint Author: "Ringelstein-Harlev, Shimrit" Database MEDLINE Remove constraint Database: MEDLINE
17 results on '"Ringelstein-Harlev, Shimrit"'

Search Results

2. Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma.

3. Eosinophilic Pleocytosis in the Cerebrospinal Fluid following CAR-T Cell Therapy for Central Nervous System Lymphoma: A Case for Warning?

4. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.

5. In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T-cell inhibitory properties, contributing to immunosuppression.

6. Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

7. Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.

8. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.

9. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.

10. Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury.

11. Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review.

12. Immune dysfunction complexity in chronic lymphocytic leukemia ‒ an issue to consider when designing novel therapeutic strategies.

13. ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia.

14. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.

15. Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

16. Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation.

17. Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting.

Catalog

Books, media, physical & digital resources